NEW YORK, March 23, 2017 /PRNewswire/ --
On Wednesday, March 22, 2017, the NASDAQ Compositeended the trading session at 5,821.64, up 0.48%; the Dow Jones Industrial Average edged 0.03% lower, to finish at 20,661.30; and the S&P 500 closed at 2,348.45, slightly gaining 0.19%. Gains were broad based as six out of nine sectors ended the day
On Wednesday, shares in Milford, Massachusetts-based Waters Corp. ended the session 0.28% higher at $155.92 with a total volume of 412,983 shares traded. Waters Corp.'s shares have advanced 0.85% in the last one month and 14.54% in the previous three months. Furthermore, the stock has gained 19.96% in the past one year. Shares of the Company, which operates as an analytical instrument manufacturer in the US and internationally, are trading at a PE ratio of 24.32. The stock is trading 4.42% above its 50-day moving average and 5.69% above its 200-day moving average. Moreover, the Company's shares have a Relative Strength Index (RSI) of 56.92. Sign up and read the free research report on WAT at:
On Wednesday, shares in Integra LifeSciences Holdings Corp. recorded a trading volume of 368,365 shares. The stock ended the day 0.52% higher at $42.90. Shares of the Company, which develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery, are trading at a PE ratio of 45.93. Integra LifeSciences' stock has gained 2.01% in the last three months and 31.68% in the previous one year. The Company's shares are trading above its 50-day and 200-day moving averages by 0.43% and 3.64%, respectively. Furthermore, Integra LifeSciences' shares have an RSI of 50.81. The complimentary research report on IART can be downloaded at:
Billerica, Massachusetts headquartered Insulet Corp.'s stock finished Wednesday's session 0.52% lower at $42.22 with a total volume of 287,722 shares traded. Over the last three months and the previous one year, Insulet's shares have gained 9.43% and 30.63%, respectively. The Company's shares are trading above its 200-day moving average by 8.70%. Shares of Insulet, which develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the US and internationally, have an RSI of 39.78.
On February 28th, 2017, research firm Wedbush reiterated its 'Outperform' rating on the Company's stock with an increase of the target price from $48 a share to $50 a share. Register for free on Stock-Callers.com and access the latest report on PODD at:
Pleasanton, California headquartered The Cooper Cos. Inc.'s stock advanced 2.28%, to close the day at $199.79. The stock recorded a trading volume of 621,594 shares, which was above its three months average volume of 424,650 shares. Cooper Cos.' shares have gained 2.22% in the last one month, 14.14% in the previous three months and 33.36% in the past one year. The Company's shares are trading 5.39% and 11.07% above its 50-day and 200-day moving averages, respectively. Shares of the Company, which operates as a medical device company worldwide, are trading at a PE ratio of 32.92. Additionally, the stock has an RSI of 67.01. Get free access to your research report on COO at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Cachexia refers to severe muscle and fat loss, anorexia and marked weight loss due to an underlying ...
Exotropia or outward eye deviation is a form of squint. Proper evaluation and timely intervention ...
Glaucoma is a group of disorders involving the optic nerve, often associated with a rise in ...View All